|1.||Holick, Michael F: 54 articles (07/2015 - 06/2002)|
|2.||Chen, Tai C: 42 articles (01/2016 - 06/2002)|
|3.||Hollis, Bruce W: 40 articles (10/2015 - 04/2004)|
|4.||Horst, Ronald L: 32 articles (06/2015 - 06/2008)|
|5.||Giovannucci, Edward: 30 articles (06/2015 - 04/2004)|
|6.||Grant, William B: 28 articles (03/2015 - 01/2004)|
|7.||Albanes, Demetrius: 26 articles (03/2015 - 10/2006)|
|8.||Weinstein, Stephanie J: 26 articles (03/2015 - 02/2009)|
|9.||Camargo, Carlos A: 24 articles (06/2015 - 02/2009)|
|10.||Li, Wei: 23 articles (12/2015 - 02/2009)|
01/01/2014 - "Thus, it is plausible to assume that rapid clearance of 1α,25(OH)2D3 by highly expressed CYP24A1 could interrupt the normal physiology of cells and might be one cause of cancer initiation and progression. "
09/01/2009 - "Most respondents felt managers treated referral to occupational health (OH) differently for employees with cancer compared with management referral for employees with other diagnoses, with 45% of respondents indicating referral may take place too late to be effective in securing a return to work. "
10/01/2012 - "To test for a possible therapeutic effect in vivo, NTera2 cells were xenografted into nude mice and treated with 1,25(OH)(2)D(3), which induced down-regulation of pluripotency factors but caused no significant reduction of tumor growth. "
01/01/1981 - "OH-BBN administration schedule had a significant effect on cancer incidence: administration of a total dose of 30, 20, or 15 mg OH-BBN in 20 weekly fractions was more effective in cancer induction than was the same total dose given in 5 fractions. "
08/01/2009 - "Gd@C(82)(OH)(22) nanoparticles are more effective in inhibiting tumor growth in mice than some clinical anticancer drugs but have negligible side effects. "
|2.||Vitamin D Deficiency
08/01/2007 - "These results indicate that 1,25(OH)(2)D(3) may play an important role in the maintenance of B cell homeostasis and that the correction of vitamin D deficiency may be useful in the treatment of B cell-mediated autoimmune disorders."
06/01/2012 - "Safe and effective food-based strategies could increase 25(OH)D across the population distribution and prevent vitamin D deficiency with potential benefit for public health."
11/15/2013 - "Our new method using DAPTAD can reduce the overestimation of the 25(OH)D3 levels, and will prove helpful in the diagnosis of vitamin D deficiency in infants."
01/01/2013 - "Using identical determinants, the RBF SVR model provided improved prediction of serum 25(OH)D concentrations and vitamin D deficiency compared with a MLR model, in this dataset."
11/01/2015 - "In conclusion, standardization of serum 25(OH)D concentrations is absolutely necessary in order to compare serum 25(OH)D concentrations across different study populations, which is needed to quantify and prevent vitamin D deficiency. "
12/01/2004 - "The levels of OC, BAP, CTx, PTH and 1,25(OH)2D were significantly greater for women with osteoporosis than for those without. "
11/20/1989 - "From the above, it was suggested that 1,25(OH)2D3 might be effective for the treatment of senile osteoporosis especially at the dose of 0.5 microgram/day."
02/07/2013 - "Moreover, the in vivo results of the ovariectomized rats further indicated that [Gd@C(82)(OH)(22)](n) nanoparticles effectively improved bone density and prevented osteoporosis."
01/01/2015 - "Thus, this study showed that 1α,25(OH)2D3 might have an inhibitory effect on the expression of MAFbx and MuRF1 in skeletal muscle and a suppressive effect on muscle degradation in patients with osteoporosis. "
04/01/2009 - "A threshold in the positive relationship between 25(OH)D and different BMD parameters was visible at a 25(OH)D level of 50 nM. Our study showed a high prevalence of low 25(OH)D in postmenopausal women with osteoporosis worldwide. "
12/01/1993 - "Conflicting results have been reported regarding the efficacy of intermittent versus continuous administration of 1,25(OH)2D3 in renal secondary hyperparathyroidism. "
10/01/1989 - "It is concluded that 3 g/day CaCO3 is equivalent to 2 g/day Al(OH)3 in terms of its phosphate-binding effect, and the prescription of CaCO3 together with 1 alpha (OH)D3 ameliorates secondary hyperparathyroidism."
11/01/2008 - "The main purpose of the present studies was to increase the knowledge of the action and effects of different treatment regimes with 1alpha(OH)D3, and thereby to improve the prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. "
07/01/2004 - "The aim of the study was to investigate the influence of 1,25(OH)2D3 therapy on long-term control of glycemia in hemodialyzed (HD) patients with severe secondary hyperparathyroidism (SHP). "
01/01/2003 - "In agreement with this new classification, in a recent study conducted in a random sample of our population, a high prevalence of low levels of 25(OH)D and secondary hyperparathyroidism was found. "
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
02/01/1990 - "1,24R(OH)2D3 may be useful in the treatment of psoriasis."
10/01/2007 - "UVB therapy in elderly psoriatic women improved psoriasis, increased serum 25(OH)D3 synthesis and reduced serum PTH concentrations."
10/01/2013 - "This population-based study in the United States evaluated 25(OH)D status in psoriasis and examined the associations between 25(OH)D and psoriasis severity. "
12/01/1986 - "Controlled trials of large numbers of patients with psoriasis vulgaris treated with 1 alpha(OH)D3 are under way."
03/01/2015 - "These prodifferentiation and antiproliferative effects of 1,25 (OH) 2D have led to its clinical use in the treatment of psoriasis. "
|2.||Cholecalciferol (Vitamin D3)
|7.||Parathyroid Hormone (Parathormone)
|1.||Renal Dialysis (Hemodialysis)
|2.||Drug Therapy (Chemotherapy)
|5.||Phototherapy (Light Therapy)